1. New Perspectives: An Oral Multikinase Inhibitor in Patients with Advanced RCC 
Bernard Escudier 
European Urology Supplements 
Volume 6, Issue 7, Pages (March 2007)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
Sorafenib is active against both tumour cell and tumour vasculature. (MEK=mitogen extracellular kinase; ERK=extracellular signal-regulated kinase; VEGFR=vascular endothelial growth factor receptor; PDGFR=platelet-derived growth factor receptor; PLC=phospholipase C; PI3K=phosphatidylinositol 3-kinase.)
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
TARGET study design. (RCC=renal cell carcinoma; ECOG PS=Eastern Cooperative Oncology Group Performance Status; MSKCC=Memorial Sloan-Kettering Cancer Centre; b.i.d.=twice daily; OS=overall survival; PFS=progression-free survival.)
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Sorafenib significantly doubled progression-free survival compared with placebo.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

5. Fig. 4
Change in tumour size from baseline in patients treated with sorafenib and placebo.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

6. Fig. 5
At the time of crossover, a trend towards improved median overall survival was observed in patients treated with sorafenib compared with placebo.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions